Although the functional relevance of the CD8+ T cell response induced by DNA and adenoviral vector vaccines coexpressing GM-CSF and antigens needs to be confirmed in relevant tumor and infection models, GM-CSF should be considered as a CD8+ T-cell adjuvant in DNA prime adenoviral vector immunization regimens. The gene discussed is CSF2; the disease is neoplasm.